InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma

Caroline J. Voskens, Duane Sewell, Ronna Hertzano, Jennifer Desanto, Sandra Rollins, Myounghee Lee, Rodney Taylor, Jeffrey Wolf, Mohan Suntharalingam, Brian Gastman, John C. Papadimitriou, Changwan Lu, Ming Tan, Robert Morales, Kevin Cullen, Esteban Celis, Dean Mann, Scott E. Strome

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. Methods Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. Results Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. Conclusion This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

Original languageEnglish (US)
Pages (from-to)1734-1746
Number of pages13
JournalHead and Neck
Volume34
Issue number12
DOIs
StatePublished - Dec 1 2012

Fingerprint

Human papillomavirus 16
Immunity
Neck
Vaccines
Head
Carcinoma
Peptides
Furin
Melanoma-Specific Antigens
Granulocyte-Macrophage Colony-Stimulating Factor
Epitopes
Blood Cells
Vaccination
HIV
Injections
Carcinoma, squamous cell of head and neck

Keywords

  • HLA-I
  • HLA-II
  • SCCHN
  • immune response
  • vaccine

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Voskens, C. J., Sewell, D., Hertzano, R., Desanto, J., Rollins, S., Lee, M., ... Strome, S. E. (2012). InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head and Neck, 34(12), 1734-1746. https://doi.org/10.1002/hed.22004

InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. / Voskens, Caroline J.; Sewell, Duane; Hertzano, Ronna; Desanto, Jennifer; Rollins, Sandra; Lee, Myounghee; Taylor, Rodney; Wolf, Jeffrey; Suntharalingam, Mohan; Gastman, Brian; Papadimitriou, John C.; Lu, Changwan; Tan, Ming; Morales, Robert; Cullen, Kevin; Celis, Esteban; Mann, Dean; Strome, Scott E.

In: Head and Neck, Vol. 34, No. 12, 01.12.2012, p. 1734-1746.

Research output: Contribution to journalArticle

Voskens, CJ, Sewell, D, Hertzano, R, Desanto, J, Rollins, S, Lee, M, Taylor, R, Wolf, J, Suntharalingam, M, Gastman, B, Papadimitriou, JC, Lu, C, Tan, M, Morales, R, Cullen, K, Celis, E, Mann, D & Strome, SE 2012, 'InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma', Head and Neck, vol. 34, no. 12, pp. 1734-1746. https://doi.org/10.1002/hed.22004
Voskens CJ, Sewell D, Hertzano R, Desanto J, Rollins S, Lee M et al. InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head and Neck. 2012 Dec 1;34(12):1734-1746. https://doi.org/10.1002/hed.22004
Voskens, Caroline J. ; Sewell, Duane ; Hertzano, Ronna ; Desanto, Jennifer ; Rollins, Sandra ; Lee, Myounghee ; Taylor, Rodney ; Wolf, Jeffrey ; Suntharalingam, Mohan ; Gastman, Brian ; Papadimitriou, John C. ; Lu, Changwan ; Tan, Ming ; Morales, Robert ; Cullen, Kevin ; Celis, Esteban ; Mann, Dean ; Strome, Scott E. / InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. In: Head and Neck. 2012 ; Vol. 34, No. 12. pp. 1734-1746.
@article{0556e5c6100244b3a6caa4d424b6856c,
title = "InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma",
abstract = "Background We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a {"}penetrin{"} peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. Methods Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. Results Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. Conclusion This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN. {\circledC} 2012 Wiley Periodicals, Inc. Head Neck, 2012",
keywords = "HLA-I, HLA-II, SCCHN, immune response, vaccine",
author = "Voskens, {Caroline J.} and Duane Sewell and Ronna Hertzano and Jennifer Desanto and Sandra Rollins and Myounghee Lee and Rodney Taylor and Jeffrey Wolf and Mohan Suntharalingam and Brian Gastman and Papadimitriou, {John C.} and Changwan Lu and Ming Tan and Robert Morales and Kevin Cullen and Esteban Celis and Dean Mann and Strome, {Scott E.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/hed.22004",
language = "English (US)",
volume = "34",
pages = "1734--1746",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - InducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma

AU - Voskens, Caroline J.

AU - Sewell, Duane

AU - Hertzano, Ronna

AU - Desanto, Jennifer

AU - Rollins, Sandra

AU - Lee, Myounghee

AU - Taylor, Rodney

AU - Wolf, Jeffrey

AU - Suntharalingam, Mohan

AU - Gastman, Brian

AU - Papadimitriou, John C.

AU - Lu, Changwan

AU - Tan, Ming

AU - Morales, Robert

AU - Cullen, Kevin

AU - Celis, Esteban

AU - Mann, Dean

AU - Strome, Scott E.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. Methods Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. Results Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. Conclusion This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

AB - Background We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. Methods Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. Results Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. Conclusion This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

KW - HLA-I

KW - HLA-II

KW - SCCHN

KW - immune response

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84869495028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869495028&partnerID=8YFLogxK

U2 - 10.1002/hed.22004

DO - 10.1002/hed.22004

M3 - Article

C2 - 22287423

AN - SCOPUS:84869495028

VL - 34

SP - 1734

EP - 1746

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

IS - 12

ER -